The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Michaël J. B. van Baar,Annemarie B. van der Aart,Klaas Hoogenberg,Jaap A. Joles,Hiddo J. L. Heerspink,Daniël H. van Raalte
DOI: https://doi.org/10.1177/2042018819865398
2019-01-01
Therapeutic Advances in Endocrinology and Metabolism
Abstract:Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.
endocrinology & metabolism
What problem does this paper attempt to address?